Multiple myeloma is a malignant tumor with abnormal proliferation of plasma cells in the bone marrow, and IgG type is common, accounting for about 50% of the total number of cases.Stage 1 and 2 myeloma is usually survived for 4 to 5 years with aggressive drug treatment, and after hematopoietic stem cell transplantation, the survival period is mostly 5 to 6 years. Of course, this must be considered in the context of whether the patient is at other high risks. The natural course of myeloma is highly heterogeneous, and the survival period varies greatly, with a median survival period of 3 to 4 years, and some patients can survive for more than 10 years. Factors affecting prognosis include age, CRP level, serum LDH level, degree of bone marrow plasma cell infiltration, renal function, ISS and R-ISS staging and cytogenetic abnormalities. If relatively young patients are in stage I or II of myeloma and are treated aggressively, the general survival period is 4 to 5 years, and after hematopoietic stem cell transplantation Survival is even longer after hematopoietic stem cell transplantation. The survival of IgG myeloma is related to many factors and should be evaluated comprehensively on a case-by-case basis.